109 related articles for article (PubMed ID: 12528473)
1. [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile].
Yasuda S; Miyata K
Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):421-6. PubMed ID: 12528473
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.
Melian EB; Plosker GL
Drugs; 2001; 61(11):1661-91. PubMed ID: 11577799
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection.
Suzuki H; Tango T
Hepatol Res; 2002 Jan; 22(1):1-12. PubMed ID: 11804828
[TBL] [Abstract][Full Text] [Related]
6. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfacon-1 protects hamsters from lethal pichinde virus infection.
Gowen BB; Barnard DL; Smee DF; Wong MH; Pace AM; Jung KH; Winslow SG; Bailey KW; Blatt LM; Sidwell RW
Antimicrob Agents Chemother; 2005 Jun; 49(6):2378-86. PubMed ID: 15917537
[TBL] [Abstract][Full Text] [Related]
8. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
Hass HG; Klein R; Nehls O; Kaiser S
J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
[TBL] [Abstract][Full Text] [Related]
9. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
10. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses.
Tan H; Derrick J; Hong J; Sanda C; Grosse WM; Edenberg HJ; Taylor M; Seiwert S; Blatt LM
J Interferon Cytokine Res; 2005 Oct; 25(10):632-49. PubMed ID: 16241862
[TBL] [Abstract][Full Text] [Related]
11. Infergen (interferon alfacon-1).
Gastroenterol Nurs; 1998; 21(1):30-1. PubMed ID: 9555366
[No Abstract] [Full Text] [Related]
12. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
Jensen DM; Krawitt EL; Keeffe EB; Hollinger FB; James SP; Mullen K; Everson GT; Hoefs JC; Fromm H; Black M; Foust RT; Pimstone NR; Heathcote EJ; Albert D
Am J Gastroenterol; 1999 Dec; 94(12):3583-8. PubMed ID: 10606323
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of virus inhibition by consensus interferon YM643.
Yasuda S; Huffman JH; Smee DF; Sidwell RW; Miyata K
Antivir Chem Chemother; 2000 Sep; 11(5):337-41. PubMed ID: 11142632
[TBL] [Abstract][Full Text] [Related]
14. [Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C].
Horban A; Wasilewski M; Berak H; Stańczak JJ; Bardadin K; Paprocka H
Przegl Epidemiol; 2006; 60(3):563-9. PubMed ID: 17249181
[TBL] [Abstract][Full Text] [Related]
15. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.
Blatt LM; Davis JM; Klein SB; Taylor MW
J Interferon Cytokine Res; 1996 Jul; 16(7):489-99. PubMed ID: 8836913
[TBL] [Abstract][Full Text] [Related]
16. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
[TBL] [Abstract][Full Text] [Related]
18. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
[TBL] [Abstract][Full Text] [Related]
19. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1.
Gowen BB; Wong MH; Jung KH; Blatt LM; Sidwell RW
Antiviral Res; 2008 Mar; 77(3):215-24. PubMed ID: 18222548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
